Previous 10 | Next 10 |
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before ...
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data support potential to address ~45% of HNSCC tumors that harbor HRAS overexpression and/or PIK3CA mutation – ...
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Of...
Gainers: Beyond Meat ( BYND ) +6% . Grindrod Shipping Holdings ( GRIN ) +5% . SpartanNash ( SPTN ) +5% . Cisco Systems ( CSCO ) +5% . Symbotic ( SYM ) +4% . Losers: Bed Bath & Beyond ( BBBY ) -19% . ...
Kura Oncology, Inc. (KURA) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Finance...
Kura Oncology press release ( NASDAQ: KURA ): Q2 GAAP EPS of -$0.52 in-line. $450 million in cash, cash equivalents and investments provide runway through 2024 For further details see: Kura Oncology GAAP EPS of -$0.52 in-line
– Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Preliminary activity observed in KURRENT-HN trial of tipifar...
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial results after ...
Kura's Phase 1b data for menin inhibitor Ziftomenib in treating NPM1 mutant and KMT2A rearranged acute myeloid leukemia, or AML, is expected this quarter. Prior data showed a complete remission in a NPM1 mutant AML patient who had failed 7 prior lines of treatment. The target mark...
Kura Oncology ( NASDAQ: KURA ) stock rises about 7% after Cantor Fitzgerald analyst Li Watsek initiated coverage with an Overweight rating and a price target of $30. The blockbuster potential of tipi combinations, and the potential of the next-generation FTI, KO-2...
News, Short Squeeze, Breakout and More Instantly...
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- ...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing...
2024-05-08 08:30:00 ET Growth stocks have resoundingly outperformed value and dividend stocks since the 2008 financial crisis. While this trend is a reversal relative to historical norms, growth stocks are likely to continue to deliver outstanding returns over the long term due to the emerg...